Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003

NCT ID: NCT01992367

Last Updated: 2016-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2014-05-31

Brief Summary

This is a single-centre, placebo-controlled, randomised, double-blind study to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of ASLAN003 in healthy subjects

Detailed Description

This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

The study is divided into two parts:

• Part A: SAD cohorts and 1 cohort to assess food effect of ASLAN003 PK.
• Part B: MAD cohorts with one cohort being of healthy elderly subjects.

There will be a sentinel pair of subjects for each of SAD Cohorts 1, 2 and 3 who will be dosed first and then the same dose will be given to the rest of the subjects in the respective cohorts.

In addition, 8 subjects will receive ASLAN003 under both fed and fasted conditions

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

placebo arm

Group Type: PLACEBO_COMPARATOR

ASLAN003 ACTIVE

Intervention Type: DRUG

This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

ASLAN003

Active drug

Group Type: OTHER

ASLAN003 ACTIVE

Intervention Type: DRUG

This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

Interventions

ASLAN003 ACTIVE

This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

Intervention Type: DRUG

Other Intervention Names

ASLAN 003 , LAS186323

Eligibility Criteria

Inclusion Criteria

• are capable of understanding and complying with the requirements of the study and have signed the informed consent form (ICF);
• are able to communicate well with the Investigator, and understand and comply with the requirements of the study;
• male subjects aged between 21 and 50 years, inclusive (Part A and Cohorts 5, 6 and 7 of Part B only); male subjects and female subjects of non childbearing potential aged ≥55 years (Cohort 8 of Part B only);
• body mass index (BMI) in the range of 18 to 30 kg/m2, inclusive;
• healthy, as determined by pre study medical history, physical examinations, vital sign measurements, electrocardiogram (ECG; 12 lead reporting RR, PR, QRS, corrected QT [QTc] and QT interval corrected for heart rate using Fridericia's formulas [QTcF]) recordings with no evidence of clinically relevant medical disorders based on the opinion of the Investigator;
• whose out-of-normal range clinical laboratory test results are not clinically relevant and are acceptable to the Investigator;
• male subjects must be willing to use barrier contraception during sexual intercourse, i.e. condoms, even if their partners are post-menopausal, surgically sterile or are using accepted contraceptive methods, from the first day of dose administrations until 3 months after the last dose administration;

Exclusion Criteria

• have participated in a study involving another investigational device or drug study within 90 days prior to randomisation in this study;
• history of drug hypersensitivity reactions or hypersensitivity to drugs chemically related to the IP;
• history or evidence of a clinically significant disorder, condition or disease (including, but not limited to, cardiopulmonary, oncologic, autoimmune, immunogenic, renal, metabolic, haematological or psychiatric), that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
• existence of any surgical or medical condition which, in the judgement of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the IP;
• clinically significant history or evidence of any active or suspected bacterial, viral, fungal or parasitic infection within the 30 days prior to randomisation (e.g. common cold, viral syndrome, flu-like symptoms, etc.);
• active or recent history (within 30 days prior to randomisation) of acute viral infection of the skin (e.g. Herpes simplex, Molluscum contagiosum);
• active or history of psoriasis, or a first-degree relative with active or history of psoriasis;
• known history or evidence of active or latent tuberculosis infection (e.g. positive tuberculin skin test showing induration >5 mm or positive tuberculin blood test) in absence of previous Bacillus Calmette Guerin vaccination, or recent exposure (within 6 months prior to randomisation in this study) to an individual with active tuberculosis or with intention to travel to a country with a high risk of tuberculosis during the study period (including the follow up period);
• history of autoimmune disease including but not limited to lupus, rheumatoid arthritis, autoimmune thyroid disease and immune thrombocytopenia;
• with QT or QTcF values higher than 450 ms at screening;
• history of regular alcohol consumption (within 6 months prior to randomisation in this study), defined as: an average weekly intake of greater than 21 units or any average daily intake of greater than 3 units. One unit is equivalent to a half pint (220 mL) of beer or 1 (25 mL) measure of spirits or 1 glass (125 mL) of wine;

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

ASLAN Pharmaceuticals

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Please contact ASLAN Pharmaceuticals Pte Ltd

Role: STUDY_DIRECTOR

contact@aslanpharma.com

Locations

Singapore, , Singapore

Countries

Singapore

Other Identifiers

ASLAN003-001

Identifier Type: -

Identifier Source: org_study_id